Odyssey Therapeutics, Inc. (ODTX)
25.17
-1.22
(-4.62%)
USD |
NASDAQ |
Aug 24, 16:00
25.17
0.00 (0.00%)
After-Hours: 19:59
Odyssey Therapeutics Enterprise Value : 978.10M for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 978.10M |
| August 20, 2026 | 895.73M |
| August 19, 2026 | 875.61M |
| August 18, 2026 | 765.46M |
| August 17, 2026 | 713.26M |
| August 14, 2026 | 707.04M |
| August 13, 2026 | 706.56M |
| August 12, 2026 | 747.74M |
| August 11, 2026 | 688.84M |
| August 10, 2026 | 776.00M |
| August 07, 2026 | 728.11M |
| August 06, 2026 | 746.31M |
| August 05, 2026 | 714.70M |
| August 04, 2026 | 670.16M |
| August 03, 2026 | 582.52M |
| July 31, 2026 | 620.83M |
| July 30, 2026 | 596.41M |
| July 29, 2026 | 578.69M |
| July 28, 2026 | 596.89M |
| July 27, 2026 | 625.62M |
| July 24, 2026 | 607.90M |
| July 23, 2026 | 560.49M |
| July 22, 2026 | 605.51M |
| July 21, 2026 | 586.83M |
| July 20, 2026 | 556.18M |
| Date | Value |
|---|---|
| July 17, 2026 | 557.62M |
| July 16, 2026 | 531.28M |
| July 15, 2026 | 540.37M |
| July 14, 2026 | 543.25M |
| July 13, 2026 | 557.62M |
| July 10, 2026 | 513.56M |
| July 09, 2026 | 520.26M |
| July 08, 2026 | 459.44M |
| July 07, 2026 | 476.20M |
| July 06, 2026 | 503.02M |
| July 02, 2026 | 518.82M |
| July 01, 2026 | 509.72M |
| June 30, 2026 | 610.30M |
| June 29, 2026 | 1.461B |
| June 26, 2026 | 1.421B |
| June 25, 2026 | 1.409B |
| June 24, 2026 | 1.441B |
| June 23, 2026 | 1.445B |
| June 22, 2026 | 1.453B |
| June 18, 2026 | 1.470B |
| June 17, 2026 | 1.442B |
| June 16, 2026 | 1.412B |
| June 15, 2026 | 1.402B |
| June 12, 2026 | 1.366B |
| June 11, 2026 | 1.361B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 4.195B |
| Alnylam Pharmaceuticals, Inc. | 31.27B |
| Anika Therapeutics, Inc. | 278.32M |
| Savara, Inc. | 1.006B |
| Vericel Corp. | 2.116B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -52.79M |
| Total Expenses (Quarterly) | 52.79M |
| EPS Diluted (Quarterly) | -1.102 |
| Earnings Yield | -14.13% |
| Normalized Earnings Yield | -13.98 |